Market Overview

Stifel No Longer Craving Molson Coors, Downgrades To Hold

Share:
Stifel No Longer Craving Molson Coors, Downgrades To Hold
Related TAP
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
Hold Your Beer: Molson Coors Is Getting Into Cannabis
Weekly Cannabis Report: Delay In Ontario Causes Selloff (Seeking Alpha)

Some drinkers think Molson Coors Brewing Co Class B (NYSE: TAP) is going flat, and they’re setting it aside for something more flavorful.

The Rating

Stifel Nicolaus analysts Mark Swartzberg, Christopher Sinnott and Ryan Robinson downgraded Molson Coors to Hold and cut their price target from $71 to $65.

The Thesis

Sales volume across the U.S. industry continues to deteriorate, and Stifel anticipates 1.5-percent annual contraction through 2030 as per capita alcohol consumption declines. These factors compound a demographic shift toward wine, spirits and higher-end beer.

“Managers are focused on improved trends across price points, but consumption patterns favor smaller, more premium brands,” the analysts wrote in a Thursday note.

Altogether, conditions render multiple expansion unlikely.

Stifel anticipates flat earnings before interest, taxes, depreciation and amortization with stock appreciation driven only by annual deleveraging.

Price Action

At time of publication, shares were set to open down about 1 percent at a rate of $59.54.

Related Links:

Trump's Tariff Decision Could Make Your Beer More Expensive: Here's How

Credit Suisse: A 'Unique Opportunity' Makes Molson Coors An Attractive Stock

Latest Ratings for TAP

DateFirmActionFromTo
Aug 2018SusquehannaMaintainsPositivePositive
Aug 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
May 2018Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for TAP
View the Latest Analyst Ratings

Posted-In: Christopher Sinnott Mark Swartzberg Ryan Robinson Stifel NicolausAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (TAP)

View Comments and Join the Discussion!

Benzinga's Top Upgrades, Downgrades For May 17, 2018

Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More